Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Agendia's ColoPrint

Premium

Agendia last week launched ColoPrint, a microarray-based test based on an 18-gene expression signature that can be used to predict the risk of distant recurrence for stage II colon cancer patients who have undergone surgery.

According to the Dutch firm, ColoPrint provides a "definitive relapse risk assessment" for 100 percent of all stage II patients and "eliminates the gray area of indeterminate results" found in patients using clinical and pathologic factors such as T4-stage and microsatellite instability status.

Agendia offers ColoPrint as a service through its labs in Amsterdam and Irvine, Calif. Agilent Technologies manufactures Agendia's arrays.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.